The U.S. Food and Drug Administration on Friday gave the nod for a new monoclonal antibody treatment that works against the Omicron variant.
The emergency use authorization for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients at least 12 years of age who are at high risk for severe disease. Eli Lilly and Co. produces the treatment. On Thursday, Lilly announced that the United States would purchase 600,000 doses of the drug in a $720 million deal.
